ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes

Keyphrases

• Tumor 100%
• Disease-free Survival 100%
• Poor Clinical Outcomes 100%
• Endometrioid Endometrial Cancer 100%
• Hazard Ratio 66%
• Overall Survival 66%
• Endometrial Cancer 66%
• Exon 10 66%
• Non-associated 33%
• In Vitro Study 33%
• Multivariate Analysis 33%
• Targeted Therapy 33%
• Cox Proportional Hazards Model 33%
• Direct Sequencing 33%
• Obstetrics 33%
• International Federations 33%
• Adjuvant Therapy 33%
• Ionizing Radiation 33%
• Contingency Table 33%
• Mutation Status 33%
• Microsatellite Instability-high (MSI-H) 33%
• Treatment Therapy 33%
• Aggressiveness 33%
• Checkpoint Kinase 1 (CHK1) 33%
• DNA Damage Response 33%
• Mutation Rate 33%
• Clinicopathological Significance 33%
• Topoisomerase Inhibitors 33%
• Truncating mutation 33%
• Endometrial Cancer Cell Line 33%
• Microsatellite Stable 33%
• DNA Mismatch Repair 33%
• Defective DNA 33%
• Individualized Treatment 33%
• DNA Damage Response Genes 33%
• Mononucleotide Repeat 33%
• Test Table 33%

Medicine and Dentistry

• Endometrial Cancer 100%
• Neoplasm 75%
• Disease Free Survival 75%
• Hazard Ratio 50%
• Overall Survival 50%
• Exon 50%
• DNA Damage Response 50%
• Malignant Neoplasm 25%
• In Vitro 25%
• Obstetrics 25%
• Targeted Therapy 25%
• Proportional Hazards Model 25%
• Biological Product 25%
• Multivariate Analysis 25%
• Cell Line 25%
• Gynecology 25%
• Ionizing Radiation 25%
• Microsatellite Instability 25%
• Adjuvant Therapy 25%
• DNA Mismatch Repair 25%
• Mutation Rate 25%
• Topoisomerase Inhibitor 25%
• Endometrial Cancer Cell Line 25%